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II and Aggrecan expression. Resultant tissue structures were vi-
sualized by SEM. One-way ANOVA was used to determine the
expression difference for each marker between the groups.
Results and Discussion: Results demonstrate the feasibility to
direct hESCs into chondrogenic lineage based on micropellet
culture and the inﬂuence of TGF-b and BMP-2 both alone and in
combination. It appears that the two growth factors have a syner-
gistic effect on the expression of chondrogenic markers, particu-
larly when TGF-b is withdrawn from Day14 onward, but BMP-2 is
present throughout the experimental period. The successful di-
rected differentiation of hESCs into cartilaginous tissue progeni-
tors supports the notion that they could be utilized as cell source in
prospective cartilage tissue engineering applications.
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For bone TE applications the formation of a prevascularized
structure is not only required for the survival of seeded cells on
scaffolds, but is also a fundamental process in bone formation
and repair. In this work we describe an in vitro strategy consist-
ing in the simultaneous culture of osteoblasts and endothelial
cells (ECs) onto a starch-based ﬁber-mesh scaffold, aiming to
accelerate the establishment of a vascular bed in the implanted
construct.
In order to distinguish between cell populations, samples were
stained after several time points for nuclei (both osteoblasts and
ECs), PECAM-1 (endothelial speciﬁc) and visualized by confocal
microscopy. After 21 days of culture the formation of tube-like
structures with PECAM-1 expression at the cell-cell junctions was
observed. The structural complexity was even higher after 35 days
with ramiﬁed tube-like structures. Immunohistochemistry of co-
culture/scaffoldcross-sections revealedthat thescaffold’svoidspaces
were ﬁlled with a dense ECM positively stained for type I collagen.
Inserted in this matrix were PECAM-stained ECs surrounding a
patent lumen. Furthermore, these tube-like structures were stained
for type IV collagen, a component of the vascular basal lamina.
Cross-talk communication between the two cell types was another
aspect under analysis. Osteoblasts in co-culture were producing
higher amounts of VEGF than in monoculture. In addition, the ex-
pression of gap junction connexin43 in the co-culture demonstrates
the heterotypic communication established between cells.
In short, the use of this co-culture system in conjunction with a
starch-based 3D scaffold holds great potential for the formation of
a prevascular network in vitro.
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Autogenetic mesenchymal stem cells (MSCs) not only can sup-
port hematopoietic stem cells (HSCs) expansion in vitro but also
alleviate complications and lead to a speedy recovery of hemato-
poiesis during hematopoietic stem cell transplantation. In order to
achieve this destination, expansion of HSCs with autogenetic
MSCs simultaneously is required. In the present study, we inves-
tigated the feasibility of expanding umbilical cord blood (UCB)
mononuclear cells (MNCs) with appearance of autogenetic MSCs
in the 3-D dynamic system without serum support. The cells were
cultured in spinner ﬂask with microcarriers and IMDM medium,
supported with the combination of cytokines, including SCF, TPO,
FL, IL-3, GM-CSF and G-CSF, and cocultured with allogeneic
UCB-MSCs encapsulated in the beads of calcium alginate-chitosan
(AC). With the diluted-feeding protocol, the total cell number,
CD34þCD45þ cells (HSCs) and CD34CD45 cells (MSCs)
could expand 2.7-fold, 9.1-fold and 8.4-fold respectively during
primary culture within 6 days. After coculture, HSCs and MSCs
can be easily separated by gravity sedimentation. At the same time,
by inducing differentiation and ﬂow cytometric analysis, the ﬁ-
broblast-like cells appeared on the surface of microcarriers could
differentiate into osteoblasts, chondrocytes and adipocytes and
expressed MSCs surface markers of CD29CD44CD105CD166
positive and CD34CD45HLA-DR negative. In conclusion we
have developed an efﬁcient protocol to expand and harvest UCB-
HSCs and UCB-MSCs simultaneously by adding cytokines and
stromal cells together with microcarriers in the dynamic culture
system.
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With more than 20,000 patients treated globally, Genzyme’s
MACI (Matrix-assisted Autologous Chondrocyte Implantation)
implants and Carticel cultured chondrocytes are used by ortho-
paedic surgeons to treat patients who have clinically signiﬁcant
articular cartilage lesions. These therapies employ the patient’s
own chrondrocytes to grow new cells for implantation. Genzyme
has over 20 years of clinical experience in developing and pro-
ducing autologous cell therapy products that meet the highest
standards of quality and compliance. In 2007, Genzyme announced
clinical data which demonstrated that Carticel cultured chon-
droncytes provided sustained and clinically meaningful improve-
ments in knee function and reduction in knee pain. In another
study, the MACI implant was demonstrated to have the ability to
generate hyaline-like cartilage as early as six months after im-
plantation. Despite the success of these cell-based therapies, al-
ternative therapies that rely solely on biomaterial scaffolds, in
some cases containing growth factors, would offer advantages in
simplicity and reduced patient morbidity. Cell-free biomaterial
approaches to cartilage repair have been the subject of a great deal
of work in academia and in industry, yet a successful cell-free
cartilage repair product remains an unmet goal. Beyond the dis-
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